Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18214808 | 0.83 | NOS2 (0.34) | TSHRNOS2 | |
| SCHEMBL31546962 | 0.73 | TSHR (0.43) | TSHRKDM4EMAPTGSK3B | |
| SCHEMBL11160281 | 0.72 | MAPT (0.41) | MAPT | |
| SCHEMBL25138321 | 0.70 | TSHR (0.41) | TSHRKDM4EMAPT | |
| SCHEMBL21533911 | 0.70 | TSHR (0.41) | TSHRKDM4EMAPT | |
| SCHEMBL18104092 | 0.70 | — | — | |
| SCHEMBL12862567 | 0.69 | GAA (0.43) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL24925793 | 0.69 | — | — | |
| SCHEMBL5447431 | 0.69 | TSHR (0.39) | TSHRKDM4EMAPTGSK3BADORA3 | |
| SCHEMBL15158947 | 0.68 | NISCH (0.38) | TSHRKDM4EMAPTNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745403-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| WO-2020123670-A1 | SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-06-18 | — | — | WO | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9512123-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | PIMERA, INC | 2016-11-10 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20110105530-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | TSHR 2881/4885KDM4E 1529/4885MAPT 4672/4885 |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | BAX, CASP3, BCL2 | TSHR 4862/4885KDM4E 2839/4885MAPT 4105/4885 |
| US-20110105530-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TSHR 4191/4885KDM4E 683/4885MAPT 2947/4885 |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | TSHR 3457/4885KDM4E 997/4885MAPT 4129/4885 |
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | TSHR 4870/4885KDM4E 2323/4885MAPT 4126/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | TSHR 4862/4885KDM4E 2839/4885MAPT 4105/4885 |
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TSHR 4191/4885KDM4E 683/4885MAPT 2947/4885 |
| US-10745403-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | TSHR 4870/4885KDM4E 2323/4885MAPT 4126/4885 |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | TSHR 346/4885KDM4E 1825/4885MAPT 3311/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | TSHR 4191/4885KDM4E 683/4885MAPT 2947/4885 |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | TSHR 4862/4885KDM4E 2839/4885MAPT 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.